SIGA Technologies, Inc. (SIGA)
USD 5.63
(3.68%)
USD 5.63
(3.68%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 122.09 Million USD | 56.9% |
| 2022 | 77.81 Million USD | -27.36% |
| 2021 | 107.12 Million USD | 7.97% |
| 2020 | 99.22 Million USD | 751.25% |
| 2019 | 11.65 Million USD | -96.84% |
| 2018 | 368.76 Million USD | 8460.67% |
| 2017 | -4.41 Million USD | 6.61% |
| 2016 | -4.72 Million USD | 4.67% |
| 2015 | -4.95 Million USD | 35.57% |
| 2014 | -7.69 Million USD | 7.76% |
| 2013 | -8.33 Million USD | 9.79% |
| 2012 | -9.24 Million USD | -172.63% |
| 2011 | 12.72 Million USD | -33.77% |
| 2010 | 19.21 Million USD | 39.13% |
| 2009 | 13.81 Million USD | 71.24% |
| 2008 | 8.06 Million USD | 20.41% |
| 2007 | 6.69 Million USD | -7.7% |
| 2006 | 7.25 Million USD | -14.38% |
| 2005 | 8.47 Million USD | 360.9% |
| 2004 | 1.83 Million USD | 151.34% |
| 2003 | 731.74 Thousand USD | 112.44% |
| 2002 | 344.45 Thousand USD | -70.29% |
| 2001 | 1.15 Million USD | -18.83% |
| 2000 | 1.42 Million USD | 58.72% |
| 1999 | 900 Thousand USD | 28.57% |
| 1998 | 700 Thousand USD | 0.0% |
| 1997 | 700 Thousand USD | 600.0% |
| 1996 | 100 Thousand USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 22.2 Million USD | -78.16% |
| 2024 Q2 | 9.49 Million USD | -57.22% |
| 2023 Q2 | -212.4 Thousand USD | -109.99% |
| 2023 Q3 | 4.69 Million USD | 2308.26% |
| 2023 Q4 | 101.67 Million USD | 2067.71% |
| 2023 Q1 | 2.12 Million USD | -47.76% |
| 2023 FY | 122.09 Million USD | 56.9% |
| 2022 Q4 | 4.07 Million USD | -93.49% |
| 2022 FY | 77.81 Million USD | -27.36% |
| 2022 Q1 | 2.27 Million USD | -97.68% |
| 2022 Q2 | 8.94 Million USD | 293.63% |
| 2022 Q3 | 62.52 Million USD | 599.05% |
| 2021 Q3 | 1.52 Million USD | -71.67% |
| 2021 Q1 | 2.26 Million USD | -92.56% |
| 2021 Q2 | 5.39 Million USD | 138.63% |
| 2021 Q4 | 97.94 Million USD | 6311.07% |
| 2021 FY | 107.12 Million USD | 7.97% |
| 2020 Q1 | -639.43 Thousand USD | -404.72% |
| 2020 FY | 99.22 Million USD | 751.25% |
| 2020 Q3 | 36.62 Million USD | 11.53% |
| 2020 Q2 | 32.84 Million USD | 5236.15% |
| 2020 Q4 | 30.39 Million USD | -17.03% |
| 2019 Q4 | 209.84 Thousand USD | -94.79% |
| 2019 Q2 | 1.86 Million USD | -66.3% |
| 2019 Q1 | 5.54 Million USD | 468.2% |
| 2019 FY | 11.65 Million USD | -96.84% |
| 2019 Q3 | 4.03 Million USD | 115.62% |
| 2018 Q2 | -650.96 Thousand USD | 48.33% |
| 2018 FY | 368.76 Million USD | 8460.67% |
| 2018 Q1 | -1.25 Million USD | 7.92% |
| 2018 Q3 | 372.18 Million USD | 57274.48% |
| 2018 Q4 | -1.5 Million USD | -100.4% |
| 2017 FY | -4.41 Million USD | 6.61% |
| 2017 Q4 | -1.36 Million USD | -26.62% |
| 2017 Q3 | -1.08 Million USD | -34.52% |
| 2017 Q2 | -803.27 Thousand USD | 30.67% |
| 2017 Q1 | -1.15 Million USD | -15.99% |
| 2016 Q1 | -1.26 Million USD | -70.08% |
| 2016 FY | -4.72 Million USD | 4.67% |
| 2016 Q3 | -1.41 Million USD | -34.68% |
| 2016 Q2 | -1.04 Million USD | 17.31% |
| 2016 Q4 | -998.97 Thousand USD | 29.16% |
| 2015 FY | -4.95 Million USD | 35.57% |
| 2015 Q3 | -1.09 Million USD | 26.32% |
| 2015 Q1 | -1.61 Million USD | 21.49% |
| 2015 Q2 | -1.49 Million USD | 7.86% |
| 2015 Q4 | -744.53 Thousand USD | 32.26% |
| 2014 Q2 | -1.72 Million USD | 23.97% |
| 2014 Q1 | -2.26 Million USD | -20.09% |
| 2014 Q3 | -1.64 Million USD | 4.55% |
| 2014 Q4 | -2.06 Million USD | -25.53% |
| 2014 FY | -7.69 Million USD | 7.76% |
| 2013 Q1 | -2.31 Million USD | 85.24% |
| 2013 FY | -8.33 Million USD | 9.79% |
| 2013 Q2 | -2.16 Million USD | 6.52% |
| 2013 Q3 | -1.96 Million USD | 9.1% |
| 2013 Q4 | -1.88 Million USD | 4.25% |
| 2012 Q3 | -1.88 Million USD | 24.23% |
| 2012 Q1 | -2.99 Million USD | -160.46% |
| 2012 FY | -9.24 Million USD | -172.63% |
| 2012 Q4 | -15.69 Million USD | -734.96% |
| 2012 Q2 | -2.48 Million USD | 17.25% |
| 2011 Q4 | 4.96 Million USD | 38.63% |
| 2011 FY | 12.72 Million USD | -33.77% |
| 2011 Q3 | 3.57 Million USD | 43.63% |
| 2011 Q2 | 2.49 Million USD | 46.82% |
| 2011 Q1 | 1.69 Million USD | -44.59% |
| 2010 Q2 | 4.44 Million USD | -12.38% |
| 2010 Q1 | 5.07 Million USD | 28.32% |
| 2010 FY | 19.21 Million USD | 39.13% |
| 2010 Q4 | 3.06 Million USD | -53.83% |
| 2010 Q3 | 6.63 Million USD | 49.14% |
| 2009 Q2 | 4 Million USD | 108.17% |
| 2009 FY | 13.81 Million USD | 71.24% |
| 2009 Q4 | 3.95 Million USD | 0.85% |
| 2009 Q3 | 3.92 Million USD | -2.17% |
| 2009 Q1 | 1.92 Million USD | -22.61% |
| 2008 FY | 8.06 Million USD | 20.41% |
| 2008 Q4 | 2.48 Million USD | 33.61% |
| 2008 Q3 | 1.86 Million USD | 7.54% |
| 2008 Q2 | 1.73 Million USD | -12.64% |
| 2008 Q1 | 1.98 Million USD | 12.49% |
| 2007 Q3 | 1.6 Million USD | 10.24% |
| 2007 Q2 | 1.45 Million USD | -21.83% |
| 2007 Q1 | 1.86 Million USD | -21.16% |
| 2007 FY | 6.69 Million USD | -7.7% |
| 2007 Q4 | 1.76 Million USD | 9.53% |
| 2006 Q4 | 2.36 Million USD | 16.35% |
| 2006 Q2 | 1.45 Million USD | 4.62% |
| 2006 Q1 | 1.39 Million USD | -37.86% |
| 2006 FY | 7.25 Million USD | -14.38% |
| 2006 Q3 | 2.03 Million USD | 39.54% |
| 2005 Q2 | 1.86 Million USD | 27.8% |
| 2005 Q3 | 2.91 Million USD | 56.12% |
| 2005 Q4 | 2.24 Million USD | -22.88% |
| 2005 FY | 8.47 Million USD | 360.9% |
| 2005 Q1 | 1.45 Million USD | 72.26% |
| 2004 Q3 | 532.72 Thousand USD | 78.44% |
| 2004 Q4 | 846.7 Thousand USD | 58.94% |
| 2004 FY | 1.83 Million USD | 151.34% |
| 2004 Q1 | 161.21 Thousand USD | 51.06% |
| 2004 Q2 | 298.53 Thousand USD | 85.18% |
| 2003 Q3 | 176.34 Thousand USD | -27.59% |
| 2003 Q1 | 205.14 Thousand USD | 77.78% |
| 2003 Q4 | 106.72 Thousand USD | -39.48% |
| 2003 FY | 731.74 Thousand USD | 112.44% |
| 2003 Q2 | 243.53 Thousand USD | 18.71% |
| 2002 Q1 | - USD | -100.0% |
| 2002 FY | 344.45 Thousand USD | -70.29% |
| 2002 Q4 | 115.39 Thousand USD | 28.59% |
| 2002 Q3 | 89.73 Thousand USD | -35.59% |
| 2002 Q2 | 139.31 Thousand USD | 0.0% |
| 2001 Q1 | 304.5 Thousand USD | -15.51% |
| 2001 FY | 1.15 Million USD | -18.83% |
| 2001 Q4 | 15 Thousand USD | -90.48% |
| 2001 Q3 | 157.5 Thousand USD | -76.92% |
| 2001 Q2 | 682.5 Thousand USD | 124.14% |
| 2000 Q2 | 347.04 Thousand USD | 23.45% |
| 2000 Q1 | 281.12 Thousand USD | 40.56% |
| 2000 FY | 1.42 Million USD | 58.72% |
| 2000 Q3 | 439.96 Thousand USD | 26.77% |
| 2000 Q4 | 360.38 Thousand USD | -18.09% |
| 1999 Q4 | 200 Thousand USD | 0.0% |
| 1999 Q1 | 200 Thousand USD | -33.33% |
| 1999 FY | 900 Thousand USD | 28.57% |
| 1999 Q3 | 200 Thousand USD | 100.0% |
| 1999 Q2 | 100 Thousand USD | -50.0% |
| 1998 Q4 | 300 Thousand USD | 50.0% |
| 1998 Q1 | 100 Thousand USD | -66.67% |
| 1998 Q2 | 100 Thousand USD | 0.0% |
| 1998 Q3 | 200 Thousand USD | 100.0% |
| 1998 FY | 700 Thousand USD | 0.0% |
| 1997 FY | 700 Thousand USD | 600.0% |
| 1997 Q1 | 100 Thousand USD | 0.0% |
| 1997 Q2 | 100 Thousand USD | 0.0% |
| 1997 Q3 | 500 Thousand USD | 400.0% |
| 1997 Q4 | 300 Thousand USD | -40.0% |
| 1996 FY | 100 Thousand USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 305.3 Million USD | 60.01% |
| Aquestive Therapeutics, Inc. | 29.75 Million USD | -310.366% |
| Collegium Pharmaceutical, Inc. | 326.16 Million USD | 62.568% |
| Cosmos Health Inc. | 4.34 Million USD | -2706.994% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 5165.694% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | -67.096% |
| Cronos Group Inc. | 6.99 Million USD | -1646.445% |
| Incannex Healthcare Limited | 12 Thousand USD | -1017334.417% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 40394.432% |
| Lifecore Biomedical, Inc. | 41.85 Million USD | -191.737% |
| Regencell Bioscience Holdings Limited | -745.58 Thousand USD | 16475.281% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | -1364.08% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | -1364.08% |
| SCYNEXIS, Inc. | 124.51 Million USD | 1.947% |
| Safety Shot Inc | -74.45 Thousand USD | 164076.698% |
| Theratechnologies Inc. | 62.12 Million USD | -96.514% |
| Alpha Teknova, Inc. | 10.29 Million USD | -1085.821% |
| Universe Pharmaceuticals INC | 10.07 Million USD | -1111.486% |
| Pacira BioSciences, Inc. | 490.3 Million USD | 75.099% |
| Sonoma Pharmaceuticals, Inc. | 4.74 Million USD | -2473.069% |
| Dynavax Technologies Corporation | 182.11 Million USD | 32.96% |
| Ironwood Pharmaceuticals, Inc. | 441.16 Million USD | 72.325% |
| Radius Health, Inc. | 307.71 Million USD | 60.322% |
| China SXT Pharmaceuticals, Inc. | 553.97 Thousand USD | -21939.444% |
| Alvotech | -69.42 Million USD | 275.87% |
| Intra-Cellular Therapies, Inc. | 430.62 Million USD | 71.648% |
| Shineco, Inc. | 882.16 Thousand USD | -13740.009% |
| Silver Spike Investment Corp. | 8.1 Million USD | -1406.827% |
| Journey Medical Corporation | 52.52 Million USD | -132.463% |
| Petros Pharmaceuticals, Inc. | 4.19 Million USD | -2813.081% |
| Embecta Corp. | 749.9 Million USD | 83.719% |
| Harrow Health, Inc. | 90.55 Million USD | -34.829% |
| Procaps Group, S.A. | 239.56 Million USD | 49.037% |
| Biofrontera Inc. | 16.62 Million USD | -634.3% |
| DURECT Corporation | 6.83 Million USD | -1687.324% |
| PainReform Ltd. | -15 Thousand USD | 814047.533% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 76.688% |
| OptiNose, Inc. | 62.35 Million USD | -95.805% |
| RedHill Biopharma Ltd. | 3.05 Million USD | -3897.551% |
| Organogenesis Holdings Inc. | 309.79 Million USD | 60.589% |
| Cumberland Pharmaceuticals Inc. | 33.48 Million USD | -264.608% |
| ProPhase Labs, Inc. | 16.23 Million USD | -651.845% |
| Phibro Animal Health Corporation | 312.48 Million USD | 60.929% |
| Procaps Group S.A. | 239.56 Million USD | 49.037% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -9277.276% |
| Viatris Inc. | 6.43 Billion USD | 98.104% |
| Rockwell Medical, Inc. | 8.7 Million USD | -1302.713% |
| Aytu BioPharma, Inc. | 54.58 Million USD | -123.669% |
| Tilray Brands, Inc. | 223.35 Million USD | 45.336% |
| PetIQ, Inc. | 252.74 Million USD | 51.693% |
| Talphera, Inc. | -4.89 Million USD | 2594.221% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 93.391% |
| Alimera Sciences, Inc. | 61.17 Million USD | -99.595% |
| Assertio Holdings, Inc. | 125.04 Million USD | 2.365% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6811.00 USD | 1792672.75% |
| Avadel Pharmaceuticals plc | 27.11 Million USD | -350.242% |
| Hempacco Co., Inc. | -1.21 Million USD | 10141.85% |
| Alvotech | -69.42 Million USD | 275.87% |
| Lantheus Holdings, Inc. | 709.54 Million USD | 82.793% |
| Kamada Ltd. | 52.59 Million USD | -132.146% |
| Currenc Group, Inc. | 17.35 Million USD | -603.445% |
| Indivior PLC | 907 Million USD | 86.539% |
| Evoke Pharma, Inc. | 4.97 Million USD | -2352.264% |
| Flora Growth Corp. | 17.73 Million USD | -588.308% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 5165.694% |
| Evolus, Inc. | 140.52 Million USD | 13.118% |
| HUTCHMED (China) Limited | 453.55 Million USD | 73.081% |
| Amphastar Pharmaceuticals, Inc. | 343.96 Million USD | 64.505% |
| Akanda Corp. | 111.44 Thousand USD | -109449.776% |